Our Science

Publications & Articles

Publications.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

ABCL575

SID Annual Meeting 2025

Preclinical development of ABCL575, a half-life extended anti-OX40L monoclonal antibody for the treatment of autoimmune conditions

T-Cell Engagers

AACR Annual Meeting 2025

PSMA x CD3 T-cell engagers show preclinical efficacy for the treatment of prostate cancer

T-Cell Engagers

SITC Annual Meeting 2024

Profiling bispecific T-cell engagers: Strategies for enhancing potency while minimizing cytokine release

T-Cell Engagers

AACR Annual Meeting 2024

Development of PSMA x CD3 T-cell engagers using an integrated, functional approach

T-Cell Engagers

AACR Annual Meeting 2024

Targeting intracellular tumor antigens to fight cancer: discovery and development of functional and specific T-cell engagers against a MAGE-A4 pMHC

Journal articles.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

mAbs

August 27, 2024

Developability considerations for bispecific and multispecific antibodies

Read article

Immunity

February 14, 2023

Highly potent, naturally acquired human monoclonal antibodies against Pfs48/45 block Plasmodium falciparum transmission to mosquitoes

Read article

Immunity

February 14, 2023

Potent transmission-blocking monoclonal antibodies from naturally exposed individuals target a conserved epitope on Plasmodium falciparum Pfs230

Read article

Cell Reports

April 17, 2022

LY-CoV1404 (bebtelovimab) potently neutralizes SARS–CoV–2 variants

Read article

Cell Reports

November 2, 2021

Stabilized coronavirus spike stem elicits a broadly protective antibody

Read article

Publications.

Preclinical development of ABCL575, a half-life extended anti-OX40L monoclonal antibody for the treatment of autoimmune conditions

PSMA x CD3 T-cell engagers show preclinical efficacy for the treatment of prostate cancer

Profiling bispecific T-cell engagers: Strategies for enhancing potency while minimizing cytokine release

Development of PSMA x CD3 T-cell engagers using an integrated, functional approach

Diverse CD28-binding antibodies for costimulatory T-cell engager development

Functional and specific T-cell engagers for a peptide-MHC tumor target

Target-dependent considerations for the design of bispecific T-cell engagers

Discovery of diverse GPCR-targeted antibodies using integrated technologies

Targeting intracellular tumor antigens to fight cancer: discovery and development of functional and specific T-cell engagers against a MAGE-A4 pMHC

Journal articles.

Developability considerations for bispecific and multispecific antibodies

Highly potent, naturally acquired human monoclonal antibodies against Pfs48/45 block Plasmodium falciparum transmission to mosquitoes

Potent transmission-blocking monoclonal antibodies from naturally exposed individuals target a conserved epitope on Plasmodium falciparum Pfs230

LY-CoV1404 (bebtelovimab) potently neutralizes SARS–CoV–2 variants

Stabilized coronavirus spike stem elicits a broadly protective antibody